GlassScriptPhysician profile
Steven M Mackay
NPI 1942254834
$8,317.86
in general payments reported to CMS, 2019-2025
31 companies · $551 in 2025
The $551 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $216 · 2021: $290 · 2022: $3,814 · 2023: $2,095 · 2024: $966 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,612.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,312.22 | 2019-2025 | Gallant, Aveir, Confirm Rx |
| Biotronik INC. | $964.73 | 2023-2024 | Biomonitor, Rivacor 7 Dr-T, Edora 8 Dr-T |
| Novartis Pharmaceuticals Corporation | $708.67 | 2019-2025 | |
| Medtronic, INC. | $560.64 | 2021-2025 | Onyx Frontier, Symplicity G3, Cg Future |
| Janssen Pharmaceuticals, INC | $347.73 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $293.46 | 2021-2025 | Avvigo Guidance System, Watchman Access System, Rotapro |
| Amgen INC. | $278.39 | 2019-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $199.45 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.03 | 2021-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $169.53 | 2019-2025 | Eliquis, Camzyos |
| Chiesi USA, INC. | $145.13 | 2022-2023 | Kengreal |
| Cvrx, INC. | $127.70 | 2024 | Barostim Neo System |
| Pfizer INC. | $122.62 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $113.40 | 2020 | |
| Novo Nordisk INC | $107.18 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.33 | 2019-2023 | Lifevest |
| Abiomed | $92.83 | 2022-2025 | Impella |
| Edwards Lifesciences Corporation | $91.59 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $57.65 | 2022-2024 | Verquvo |
| Atricure, INC. | $50.39 | 2023 | |
| Acist Medical Systems, INC. | $49.59 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $42.44 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $40.59 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $32.56 | 2022 | |
| Cardiovascular Systems INC. | $24.71 | 2019-2022 | |
| Genzyme Corporation | $19.94 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $18.84 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $17.54 | 2023 | Injectafer |
| Philips North America LLC | $15.72 | 2024 | (Bs1) Peripheral Vascular Undivided |
| Alnylam Pharmaceuticals INC. | $15.21 | 2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $15.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mackay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.